David Boulware, MD MPH
David Boulware, MD MPH

@boulware_dr

8 Tweets 4 reads Jan 21, 2024
@TogetherTrial has completed a sensitivity analysis for its metformin outpatient #COVID19 trial
Receiving metformin was NOT an exclusion criterion for the trial. Gving 1500mg/d on top of existing metformin was not great. Odds Ratio =1.35 for ER/hospital
But Odds Ratio=0.59 if not
The overall updated results of the trial testing metformin (after some data cleaning, rerunning the results), including people taking metformin at baseline who were then randomized to receive +1500mg/d metformin XR or blinded placebo on top of all their existing meds, was:
But the more interesting sensitivity analysis of the TogetherTrial #metformin #COVID19 double-blind randomized trail is only considering those 368 particiapnts NOT already receiving metformin at baseline. #IDTwitter
37% reduction in ER visits/hospitalizations sounds similar...
Though a strong bias exists against a low cost $1 med available globally, nothing says that one cannot spend $1300 for #paxlovid + $1 for #metformin.
one of these has evidence of benefit in 2 randomized #COVID19 trials, including in people vaccinated.
@IDSAInfo #IDtwitter
If you or someone you know have #COVID19 and risk factors for disease progression (older, overweight, heart or lung disease), consider volunteering for @ACTIV6study to test metformin.
Volunteer at activ6study.org
Not prohibited from taking other meds, such as #paxlovid
Overall, we need more clinical trials on the effects of various therapies in different populations to determine who benefit in a population with prior infection / vaccination.

Loading suggestions...